UDG Healthcare Public Limited Co. Notice of Interim Results (9202D)
May 03 2017 - 2:01AM
UK Regulatory
TIDMUDG
RNS Number : 9202D
UDG Healthcare Public Limited Co.
03 May 2017
3 May 2017
UDG Healthcare plc
Notice of Interim Results
UDG Healthcare plc ("the Group"), a leading international
healthcare services provider, will issue its interim results for
the half year ended 31 March 2017 at 07:00am (BST) on Tuesday 23
May 2017.
Brendan McAtamney, CEO and Alan Ralph, CFO will be hosting a
presentation for analysts and investors at the London Stock
Exchange at 08:30am (BST) to discuss the company's half year
results and provide an update on each of the Group's divisions.
Analysts and investors wishing to attend are asked to contact
Powerscourt on the details below, as all attendees need to be
pre-registered. The presentation will also be available via live
audio webcast and conference call, the details of which are
below.
Audio webcast:
http://edge.media-server.com/m/p/ee9kdegt
Conference call dial-in details:
UK +44-(0)203-427-1903
-------------------------- --------------------
Ireland +353-1-246-5603
-------------------------- --------------------
United States of America +1-646-254-3388
-------------------------- --------------------
Participant Code 1935522
-------------------------- --------------------
For further information, please contact:
UDG Healthcare plc
Keith Byrne
Head of Investor Relations, Strategy
& Corporate Communications
Tel: +353-1-468-9000
Powerscourt
Lisa Kavanagh / Nick Brown
Tel: +44-207-250-1446
udghealthcare@powerscourt-group.com
About UDG Healthcare plc:
UDG Healthcare plc (LON: UDG) is a leading international partner
of choice delivering commercial, clinical, communications and
packaging services to the healthcare industry, employing over 8,000
people with operations in 23 countries and delivering services in
over 50 countries.
UDG Healthcare plc operates across three divisions: Ashfield,
Sharp and Aquilant.
Ashfield is a global leader in commercialisation services for
the pharmaceutical and healthcare industry, operating across two
broad areas of activity: commercial & clinical services, and
communications services. It focuses on supporting healthcare
professionals and patients at all stages of the product life cycle.
The division provides field and contact centre sales teams,
healthcare communications, patient support, audit, advisory,
medical information and event management services to over 300
healthcare companies.
Sharp is a global leader in contract commercial packaging and
clinical trial packaging services for the pharmaceutical and
biotechnology industries, operating from state of the art
facilities across the US and Europe. Sharp is also a world leader
in 'Track and Trace' serialisation services, which will require all
prescription drugs to have a unique serial code for authentication
and traceability.
Aquilant is a leading provider of outsourced sales, marketing,
distribution and engineering services to the medical and scientific
sectors in the UK, Ireland and the Netherlands.
The company is listed on the London Stock Exchange and is a
constituent of the FTSE 250.
For more information, please go to: www.udghealthcare.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
NORSSIFEEFWSEEI
(END) Dow Jones Newswires
May 03, 2017 02:01 ET (06:01 GMT)
Udg Healthcare Public (LSE:UDG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Udg Healthcare Public (LSE:UDG)
Historical Stock Chart
From Apr 2023 to Apr 2024